About us   Contacts   Links   Information in Russian 
Research programms
Journal
Bulletin of the Multinational Center for Quality of Life Research

Bulletin of the Multinational Center of Quality of Life Research





T. I. Ionova1, K. V. Lepik2, N. B. Mikhailova2, T. P. Nikitina1, N.M.Porfirieva1, L. V. Fedorova2, B. V. Afanasiev2

Quality of life in patients with relapsed/refractory Hodgkin lymphoma receiving nivolumab in real clinical practice

1MULTINATIONAL CENTER FOR QUALITY OF LIFE RESEARCH, SAINT-PETERSBURG
2RAISA GORBACHEVA MEMORIAL RESEARCH INSTITUTE OF CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION, I. P. PAVLOV FIRST SAINT-PETERSBURG STATE MEDICAL UNIVERSITY, SAINT-PETERSBURG

Comprehensive evaluation of treatment outcomes in relapsed/refractory classical Hodgkin lymphoma (cHL) is worthwhile. The aim of the present study is to evaluate quality of life (QoL) and symptoms in patients with relapsed/refractory classical Hodgkin lymphoma receiving nivolumab in a real clinical setting. The total of 100 patients with the confirmed relapsed/refractory classical Hodgkin lymphoma were enrolled in the study (the median age 33 years, 52 % — men). All the patients filled out questionnaires for QoL assessment (RAND SF-36, EQ-5D) and symptoms assessment (CSP Lym) before nivolumab treatment start, in 3, 6, 9 and 12 months after an initiation of treatment. Nivolumab therapy was accompanied by remarkable QoL improvement and decrease of symptoms during 12 months of treatment with nivolumab (GEE, p<0,05). The proportion of patients with a significant QoL impairment decreased during 12 months of therapy with nivolumab as compared with baseline (p < 0,05). During nivolumab treatment a decrease in the severity of the vast majority of estimated symptoms was observed (p<0,05). The results obtained demonstrate benefits of nivolumab treatment from patients’ perspective. These data confirm the importance of patient-reported outcomes when assessing the effects of treatment in patients with relapsed/refractory classical Hodgkin lymphoma.




© Создание сайтов

Последнее обновление (last update): 29-05-2024









Яндекс цитирования